Search for a trial

1 results

An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and
immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombocytopenic purpura

Approved WMORecruiting

This study has been transitioned to CTIS with ID 2024-513262-19-00 check the CTIS register for the current data. Primary objective:- To evaluate the efficacy of caplacizumab in combination with immunosuppressive therapy (IST) without therapeutic…

An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombocytopenic purpura

An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and
immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombocytopenic purpura